From DCAT Value Chain Insights (VCI)
Mylan N.V. has appointed Ranjan Ray Chaudhuri to serve as global commercial lead of the company's over-the-counter (OTC) business. Chaudhuri will report to Rajiv Malik, president of Mylan.
Chaudhuri joins Mylan from GlaxoSmithKline (GSK) Consumer Healthcare, where he served for nearly three decades. During his time at GSK, Chaudhuri was responsible for the company's global smoking reduction and cessation category, which included NiQuitin and other nicotine replacement therapies (NRTs). In addition, Chaudhuri led the development of an innovative program designed to leverage NRTs along with other GSK respiratory products, such as Advair and Seretide. Prior to that, Chaudhuri served as innovation director for GSK's smoking control and cold sore franchises, driving double-digit sales growth in the latter through product launches and creative advertising.
Chaudhuri alsp recently led the divestiture of an OTC portfolio of NRT products to Perrigo, a move prompted by GSK's formation of a consumer healthcare joint venture with Novartis.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription